Cleveland Clinic Heart Failure Summit Expanding the Frontiers of Contemporary Team Management 2025

Cleveland Clinic Heart Failure Summit Expanding the Frontiers of Contemporary Team Management 2025

Information:

• Apply appropriate strategies to optimize use of current and novel drug therapy of heart failure with reduced left ventricular ejection fraction
• Describe how to utilize medical devices and surgical therapies in the care of heart failure patients
• Discuss the clinical profile of heart failure and differentiate between reduced and preserved ejection fraction patients
• Discuss the latest findings concerning pharmacological approaches to heart failure with midrange or preserved ejection fraction
• Employ current therapeutic strategies for cardiac amyloid and hypertrophic cardiomyopathy
• Identify options for electrophysiological interventions to address risk of sudden death and atrial arrhythmias in patients with heart failure
• Who Should Attend?

 Topics:

• Agenda.pdf
• June 6 Advanced evaluation of the breathless patient.pdf
• June 6 AF ablation and the pulsed field era.pdf
• June 6 Arrhythmogenic cardiomyopathies and genetic testing.pdf
• June 6 Breakthroughs in obesity-related HFpEF.pdf
• June 6 Cardiac contractility modulation.pdf
• June 6 Current and emerging device-based therapies for HFpEF.pdf
• June 6 Educating and engaging the patient of tomorrow.pdf
• June 6 GDMT optimization across the inpatient-outpatient domain.pdf
• June 6 Harnessing tech for GDMT optimization and readmission reduction.pdf
• June 6 Harnessing the heart team for GDMT equity.pdf
• June 6 HF STATS The changing face of heart failure.pdf
• June 6 Lessons learnt for diverse HF trial recruitment.pdf
• June 6 New insights into HFpEF mechanisms.pdf
• June 6 Novel therapies for cardiomyopathies.pdf
• June 6 Remote monitoring in the “AI era”- Leveraging new devices and algorithms.pdf
• June 6 Remote monitoring the “old school” way- Weights, vitals and symptoms.pdf
• June 6 Session 1 – Updates in HF Epidemiology and Population Health.mp4
• June 6 Session 2 – HFrEF and EP Innovations.mp4
• June 6 Session 3 – HFpEF and Pulmonary Hypertension.mp4
• June 6 Session 4A – Meet the Clinical Trialists (Concurrent Session).mp4
• June 6 The future of remote HF and EP monitoring.pdf
• June 6 The LAA and controversies in anticoagulation.pdf
• June 6 The next frontier- earlier diagnosis and treatment of HF.pdf
• June 6 The next generation HFrEF therapies.pdf
• June 6 Trials and tribulations in valvular interventions.pdf
• June 6 Ventricular tachycardia in patients with HFrEF.pdf
• June 6 What’s new in pulmonary hypertension.pdf
• June 7 A positive PET scan- What comes next.pdf
• June 7 Collapse to comeback- Improving outcomes after cardiac arrest.pdf
• June 7 DanGer ahead- Seeking an evidence base for shock management.pdf
• June 7 Evolutions in organ preservation and transportation.pdf
• June 7 Fixing the flow- Revascularization for the high-risk patient.pdf
• June 7 Getting shock right- Managing the right ventricle.pdf
• June 7 HCM in the era of myosin inhibition.pdf
• June 7 LVADs in a Transplant World.pdf
• June 7 Managing MCS at a non-transplant center.pdf
• June 7 Managing TTR cardiac amyloidosis in 2025.pdf
• June 7 Multidisciplinary cardiac care during pregnancy.pdf
• June 7 Post-heart transplant outcomes and management innovations.pdf
• June 7 Session 1 – Cardiomyopathies (amyloid, HCM, Sarcoid) and HFrEF.mp4
• June 7 Session 2 – MCS and TX.mp4
• June 7 Session 3 – Cardiogenic shock and critical care.mp4
• June 7 The next generation of LVADs and trials.pdf
• June 7 Transplant and VAD options in congenital conditions.pdf